BeyondSpring Inc. (BYSI)
BYSI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/0001171843-26-001908-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BYSI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001677940 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$1.0M |
| Operating income | -$8.9M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $7.8M |
| Total assets | $25.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $2.7M cash; operating cash flow -$4.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 41,119,820 (2026-07-31); 40,332,320 a year earlier. | Cover page 2026-07-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-09-29 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-10-02 |
| Auditor | CBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $553K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$849K | -$3.8M | $2.7M | No debt tags | $0 | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $0 | -$2.2M | -$3.3M | $4.0M | No debt tags | $0 | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $0 | -$2.1M | -$5.5M | $7.8M | No debt tags | $0 | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $0 | -$1.5M | -$4.2M | $12.5M | No debt tags | $0 | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $0 | -$1.8M | -$5.9M | $9.5M | No debt tags | $0 | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $0 | $4.5M | -$4.2M | $6.5M | No debt tags | $0 | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $0 | -$1.7M | $982K | $2.9M | No debt tags | $0 | 10-K 2026-03-25 |
| Q3 2024 2024-09-30 | $0 | -$2.1M | -$5.2M | $19.3M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-29 |
| Latest annual report FORM 10-K | 10-K | 2026-03-25 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-16 |
| Latest current report FORM 8-K | 8-K | 2026-11-13 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-09-03 |
Source: SEC EDGAR submissions feed, 266 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.0% |
| 1 month | -1.0% |
| 3 months | -39.7% |
| Year to date | -63.1% |
| 1 year | -70.8% |
| From 52-week high | -74.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FLNA | Filana Therapeutics Inc. | $0.4700 | +10.56% | $23.6M |
| GRDX | GridAI Technologies Corp. | $3.30 | -11.76% | $23.5M |
| IXHL | Incannex Healthcare Inc. | $1.93 | -2.03% | $24.2M |
| RNAZ | TransCode Therapeutics Inc. | $1.35 | -1.46% | $22.9M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier